Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03764618




Registration number
NCT03764618
Ethics application status
Date submitted
3/12/2018
Date registered
5/12/2018
Date last updated
25/05/2023

Titles & IDs
Public title
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA
Scientific title
A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Secondary ID [1] 0 0
C-935788-057
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Warm Antibody Autoimmune Hemolytic Anemia 0 0
Condition category
Condition code
Blood 0 0 0 0
Anaemia
Blood 0 0 0 0
Anaemia
Blood 0 0 0 0
Haematological diseases
Inflammatory and Immune System 0 0 0 0
Autoimmune diseases
Blood 0 0 0 0
Other blood disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Fostamatinib disodium
Treatment: Drugs - Placebo

Experimental: Fostamatinib - Initial dose is 100 mg by mouth (PO) twice a day (bid). At week 4 dose will be increased to fostamatinib 150 mg PO bid if subjects have adequately tolerated the study drug in the opinion of the Investigator.

Placebo Comparator: Placebo - Initial dose is 100 mg by mouth (PO) twice a day (bid). At week 4 dose will be increased to placebo 150 mg PO bid if subjects have adequately tolerated the study drug in the opinion of the Investigator.


Treatment: Drugs: Fostamatinib disodium
Fostamatinib (100mg PO bid or 150 mg PO bid)
The dose may be reduced at any time to a dose as low as fostamatinib 100 mg PO qd or matching placebo if dose limiting adverse events are observed.

Treatment: Drugs: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Durable Hemoglobin Response
Timepoint [1] 0 0
24 Weeks
Secondary outcome [1] 0 0
A Hemoglobin Response by Week 24
Timepoint [1] 0 0
24 weeks
Secondary outcome [2] 0 0
Change From Baseline in Hemoglobin Level of 2 g/dL or Greater
Timepoint [2] 0 0
24 weeks
Secondary outcome [3] 0 0
Change in Hemoglobin From Baseline to End of Treatment
Timepoint [3] 0 0
24 weeks
Secondary outcome [4] 0 0
Use of Rescue Antibody Autoimmune Hemolytic Anemia (AIHA) Regimens Use After Week 4
Timepoint [4] 0 0
24 weeks
Secondary outcome [5] 0 0
Change in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F)
Timepoint [5] 0 0
24 weeks

Eligibility
Key inclusion criteria
1. Subject must have a diagnosis of primary or secondary warm Antibody Autoimmune
Hemolytic Anemia (wAIHA) as documented by a positive direct antiglobulin test (DAT)
specific for anti-IgG or anti-IgA.

2. Have failed or not tolerated at least one prior wAIHA treatment regimen, including
steroids, rituximab, azathioprine, cyclophosphamide, cyclosporine, MMF, danazol,
vincristine, ESA or splenectomy (folate, iron or other supplements do not fulfill this
criterion).

3. Have haptoglobin <LLN or total bilirubin >ULN or lactate dehydrogenase (LDH) >ULN.

4. At screening, subject's hemoglobin level must be =9 g/dL OR if hemoglobin value >9
g/dL and <10 g/dL, subject must be on an allowed wAIHA treatment AND the subject must
have documented symptoms related to anemia (e.g., weakness, dizziness, fatigue,
shortness of breath, chest pain).

5. Karnofsky performance status (KPS) =70.

6. Subject's concurrent treatment for wAIHA may consist of no more than two of any of the
following agents: azathioprine, steroids, ESAs, mycophenolate mofetil, dapsone or
danazol at a stable dose
Minimum age
18 Years
Maximum age
100 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Subject with other types of Antibody Autoimmune Hemolytic Anemia (AIHA) (e.g., cold
antibody AIHA, cold agglutinin syndrome, mixed type AIHA, or paroxysmal cold
hemoglobinuria).

2. Subject has AIHA secondary to autoimmune disease, including systemic lupus
erythematosus (SLE), or lymphoid malignancy if the underlying disease is not stable or
is not well-controlled on current therapy, per investigator medical judgement.

3. Subject has uncontrolled or poorly controlled hypertension, defined as systolic blood
pressure =135 mmHg or diastolic blood pressure =85 mmHg, whether or not the subject is
receiving anti-hypertensive treatment.

4. Subject has one or more of the following laboratory abnormalities at screening:
neutrophil count of <1,000/µL or platelet count of <30,000/µL, unless due to Evans
syndrome; transaminase levels (i.e., alanine aminotransferase [ALT] or aspartate
aminotransferase [AST]) >1.5 x ULN.

5. Has documented active hepatitis B or hepatitis C infection or HIV infection.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
24/04/2019
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
11/04/2022
Sample size
Target
Accrual to date
Final
90
Recruitment in Australia
Recruitment state(s)
NSW,QLD,VIC,WA
Recruitment hospital [1] 0 0
Concord Repatriation General Hospital - Sydney
Recruitment hospital [2] 0 0
Princess Alexandra Hospital - Cancer Trials Unit - Brisbane
Recruitment hospital [3] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [4] 0 0
Royal Perth Hospital - Perth
Recruitment postcode(s) [1] 0 0
2139 - Sydney
Recruitment postcode(s) [2] 0 0
4201 - Brisbane
Recruitment postcode(s) [3] 0 0
3004 - Melbourne
Recruitment postcode(s) [4] 0 0
6000 - Perth
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Georgia
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Maryland
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Nevada
Country [11] 0 0
United States of America
State/province [11] 0 0
New Jersey
Country [12] 0 0
United States of America
State/province [12] 0 0
New York
Country [13] 0 0
United States of America
State/province [13] 0 0
North Carolina
Country [14] 0 0
United States of America
State/province [14] 0 0
South Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Texas
Country [16] 0 0
United States of America
State/province [16] 0 0
Washington
Country [17] 0 0
United States of America
State/province [17] 0 0
Wisconsin
Country [18] 0 0
Austria
State/province [18] 0 0
Innsbruck
Country [19] 0 0
Austria
State/province [19] 0 0
Salzburg
Country [20] 0 0
Austria
State/province [20] 0 0
Vienna
Country [21] 0 0
Austria
State/province [21] 0 0
Wien
Country [22] 0 0
Belarus
State/province [22] 0 0
Vitebsk
Country [23] 0 0
Belgium
State/province [23] 0 0
Antwerpen
Country [24] 0 0
Belgium
State/province [24] 0 0
Edegem
Country [25] 0 0
Belgium
State/province [25] 0 0
Sint-Niklaas
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Pleven
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Sofia
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Varna
Country [29] 0 0
Canada
State/province [29] 0 0
Ontario
Country [30] 0 0
Czechia
State/province [30] 0 0
Brno
Country [31] 0 0
Czechia
State/province [31] 0 0
Ostrava
Country [32] 0 0
Czechia
State/province [32] 0 0
Praha
Country [33] 0 0
Denmark
State/province [33] 0 0
Aalborg
Country [34] 0 0
Denmark
State/province [34] 0 0
Aarhus N
Country [35] 0 0
Denmark
State/province [35] 0 0
Herlev
Country [36] 0 0
France
State/province [36] 0 0
Angers
Country [37] 0 0
France
State/province [37] 0 0
Caen
Country [38] 0 0
France
State/province [38] 0 0
Clermont-Ferrand
Country [39] 0 0
France
State/province [39] 0 0
Créteil
Country [40] 0 0
France
State/province [40] 0 0
Paris
Country [41] 0 0
France
State/province [41] 0 0
Pessac
Country [42] 0 0
France
State/province [42] 0 0
Toulouse
Country [43] 0 0
Georgia
State/province [43] 0 0
Tbilisi
Country [44] 0 0
Germany
State/province [44] 0 0
Essen
Country [45] 0 0
Germany
State/province [45] 0 0
Leipzig
Country [46] 0 0
Hungary
State/province [46] 0 0
Budapest
Country [47] 0 0
Hungary
State/province [47] 0 0
Nyíregyháza
Country [48] 0 0
Hungary
State/province [48] 0 0
Pécs
Country [49] 0 0
Italy
State/province [49] 0 0
Brescia
Country [50] 0 0
Italy
State/province [50] 0 0
Milano
Country [51] 0 0
Italy
State/province [51] 0 0
Novara
Country [52] 0 0
Italy
State/province [52] 0 0
Trieste
Country [53] 0 0
Italy
State/province [53] 0 0
Vicenza
Country [54] 0 0
Netherlands
State/province [54] 0 0
Amsterdam
Country [55] 0 0
Norway
State/province [55] 0 0
Bergen
Country [56] 0 0
Norway
State/province [56] 0 0
Grålum
Country [57] 0 0
Norway
State/province [57] 0 0
Ålesund
Country [58] 0 0
Romania
State/province [58] 0 0
Bucharest
Country [59] 0 0
Romania
State/province [59] 0 0
Cluj-Napoca
Country [60] 0 0
Russian Federation
State/province [60] 0 0
Moscow
Country [61] 0 0
Russian Federation
State/province [61] 0 0
Novosibirsk
Country [62] 0 0
Russian Federation
State/province [62] 0 0
Sochi
Country [63] 0 0
Russian Federation
State/province [63] 0 0
Tomsk
Country [64] 0 0
Serbia
State/province [64] 0 0
Belgrade
Country [65] 0 0
Serbia
State/province [65] 0 0
Niš
Country [66] 0 0
Serbia
State/province [66] 0 0
Novi Sad
Country [67] 0 0
Spain
State/province [67] 0 0
Barcelona
Country [68] 0 0
Spain
State/province [68] 0 0
Madrid
Country [69] 0 0
Spain
State/province [69] 0 0
Sevilla
Country [70] 0 0
Spain
State/province [70] 0 0
Valencia
Country [71] 0 0
Ukraine
State/province [71] 0 0
Cherkasy
Country [72] 0 0
Ukraine
State/province [72] 0 0
Dnipro
Country [73] 0 0
Ukraine
State/province [73] 0 0
Kyiv
Country [74] 0 0
United Kingdom
State/province [74] 0 0
Kent
Country [75] 0 0
United Kingdom
State/province [75] 0 0
Liverpool
Country [76] 0 0
United Kingdom
State/province [76] 0 0
London
Country [77] 0 0
United Kingdom
State/province [77] 0 0
West Bromwich

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Rigel Pharmaceuticals
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The primary objective of this study is to assess the efficacy of fostamatinib in subjects
with warm antibody autoimmune hemolytic anemia (wAIHA).
Trial website
https://clinicaltrials.gov/ct2/show/NCT03764618
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03764618